These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 2082833)

  • 21. Anti-NuMA antibodies: an uncommon specificity in scleroderma sera.
    Herrera-Esparza R; Avalos-Diaz E; Barbosa-Cisneros O
    Rev Rhum Engl Ed; 1999 Jun; 66(6):315-8. PubMed ID: 10418059
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Scl 70 antibody--a specific marker of systemic sclerosis.
    Jarzabek-Chorzelska M; Blaszczyk M; Jablonska S; Chorzelski T; Kumar V; Beutner EH
    Br J Dermatol; 1986 Oct; 115(4):393-401. PubMed ID: 3535866
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vascular endothelial cell injury in progressive systemic sclerosis and other connective tissue diseases.
    Meyer O; Haïm T; Dryll A; Lansaman J; Ryckewaert A
    Clin Exp Rheumatol; 1983; 1(1):29-34. PubMed ID: 6442633
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IgG antiendothelial cell autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro. Induction of adhesion molecule expression and involvement of endothelium-derived cytokines.
    Carvalho D; Savage CO; Black CM; Pearson JD
    J Clin Invest; 1996 Jan; 97(1):111-9. PubMed ID: 8550821
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostacyclin production by human umbilical vein endothelium in response to serum from patients with systemic sclerosis.
    Holt CM; Moult J; Lindsey N; Hughes P; Greaves M; Rowell NR
    Br J Rheumatol; 1989 Jun; 28(3):216-20. PubMed ID: 2659125
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tissue specificity of antinuclear antibodies in scleroderma.
    Błaszczyk M; Beutner EH; Rogoziński T; Rzesa G; Jarzabek-Chorzelska M; Jabłońska S; Chorzelski TP
    Arch Immunol Ther Exp (Warsz); 1978; 26(1-6):761-4. PubMed ID: 107922
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Localization of the centromere protein CENP-B using scleroderma sera and evidence for a role in centromere survival.
    Barbosa-Cisneros O; Avalos-Diaz E; Vera O; Moreno J; Herrera-Esparza R
    Rev Rhum Engl Ed; 1998 Jan; 65(1):15-20. PubMed ID: 9523381
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Substrate specificity of antinuclear antibodies in scleroderma.
    Blaszczyk M; Beutner EH; Rogozinski T; Rzesa G; Jarzabek-Chorzelska M; Jablonska S; Chorzelski TP
    J Invest Dermatol; 1977 Apr; 68(4):191-3. PubMed ID: 66298
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pathophysiological effects of endothelial cytotoxic activity derived from sera of patients with progressive systemic sclerosis.
    Drenk F; Deicher HR
    J Rheumatol; 1988 Mar; 15(3):468-74. PubMed ID: 3379623
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comprehensive investigation of disease-specific short peptides in sera from patients with systemic sclerosis: complement C3f-des-arginine, detected predominantly in systemic sclerosis sera, enhances proliferation of vascular endothelial cells.
    Xiang Y; Matsui T; Matsuo K; Shimada K; Tohma S; Nakamura H; Masuko K; Yudoh K; Nishioka K; Kato T
    Arthritis Rheum; 2007 Jun; 56(6):2018-30. PubMed ID: 17530642
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Anti-centromere antibody (ACA) and its significance for the diagnosis of CREST syndrome].
    Chen SE; Gu YY; Xu YH
    Zhonghua Nei Ke Za Zhi; 1986 Dec; 25(12):736-8, 776. PubMed ID: 3494576
    [No Abstract]   [Full Text] [Related]  

  • 32. [Anticentromere antibodies and other antinuclear antibodies in progressive systemic sclerosis].
    Rojas C; Silva MC; Pérez L; Ruiz F
    Rev Med Chil; 1985 May; 113(5):409-14. PubMed ID: 3912881
    [No Abstract]   [Full Text] [Related]  

  • 33. Anticentromere antibody and immunoglobulin allotypes in scleroderma.
    Chen ZY; Fedrick JA; Pandey JP; Silver R; Maricq HR; Fudenberg HH; Dobson RL; Ainsworth SK
    Arch Dermatol; 1985 Mar; 121(3):339-44. PubMed ID: 3883903
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Antinuclear antibodies in progressive systemic sclerosis].
    Sepúlveda C; Palma S; Guzmán L; Bravo M
    Rev Med Chil; 1986 Aug; 114(8):731-6. PubMed ID: 3554436
    [No Abstract]   [Full Text] [Related]  

  • 35. Antimyenteric neuronal antibodies in scleroderma.
    Howe S; Eaker EY; Sallustio JE; Peebles C; Tan EM; Williams RC
    J Clin Invest; 1994 Aug; 94(2):761-70. PubMed ID: 8040331
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Antinuclear antibodies in patients with systemic scleroderma].
    Wranicz A; Defecińska-Trzeciak E
    Przegl Dermatol; 1972; 59(3):315-20. PubMed ID: 4538127
    [No Abstract]   [Full Text] [Related]  

  • 37. [What can be expected of biological tests in scleroderma?].
    Meyer O
    Ann Med Interne (Paris); 1984; 135(8):584-90. PubMed ID: 6335633
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Scleroderma--systemic sclerosis. Serology, lung function and survival].
    Ullman S; Halberg P; Wiik A; Jacobsen S
    Ugeskr Laeger; 1999 May; 161(21):3084-90. PubMed ID: 10377851
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antinuclear antibodies in patients with Raynaud's phenomenon: clinical significance of anticentromere antibodies.
    Kallenberg CG; Pastoor GW; Wouda AA; The TH
    Ann Rheum Dis; 1982 Aug; 41(4):382-7. PubMed ID: 7051989
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Platelet activation, endothelial cell dysfunction in the absence of anticardiolipin antibodies in systemic sclerosis.
    Lima J; Fonollosa V; Fernández-Cortijo J; Ordi J; Cuenca R; Khamashta MA; Vilardell M; Simeón CP; Picó M
    J Rheumatol; 1991 Dec; 18(12):1833-6. PubMed ID: 1839040
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.